GENFIT’s (GNFT) “Sell (D)” Rating Reaffirmed at Weiss Ratings

Weiss Ratings reissued their sell (d) rating on shares of GENFIT (NASDAQ:GNFT) in a research note issued to investors on Tuesday morning,Weiss Ratings reports.

Separately, HC Wainwright lowered their target price on shares of GENFIT from $9.00 to $7.00 and set a “buy” rating on the stock in a report on Wednesday, September 24th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $7.00.

GENFIT Stock Performance

Shares of GNFT stock opened at $4.10 on Tuesday. The company’s fifty day simple moving average is $4.01 and its two-hundred day simple moving average is $3.93. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.74 and a quick ratio of 3.74. GENFIT has a 1 year low of $2.55 and a 1 year high of $6.42.

Institutional Trading of GENFIT

An institutional investor recently bought a new position in GENFIT stock. OLD Mission Capital LLC acquired a new stake in shares of GENFIT S.A. Unsponsored ADR (NASDAQ:GNFT) during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 22,238 shares of the company’s stock, valued at approximately $76,000. Hedge funds and other institutional investors own 2.24% of the company’s stock.

About GENFIT

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.